|
Sep 26
|
Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to January 31, 2025
|
|
Aug 1
|
Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Month Ended July 31, 2024
|
|
Jul 24
|
Scilex Holding Company Announces Publication of Its Inaugural Sustainability Report
|
|
Jul 23
|
Scilex Holding Company Strengthens Board of Directors with Appointment of Highly Accomplished Leader in Interventional and Multidisciplinary Spine, Musculoskeletal and Orthopedic Care, Annu Navani, M.D.
|
|
Jun 20
|
Scilex Holding Company Partners with New National Distributor, Endeavor Distribution LLC.
|
|
Jun 14
|
Scilex Holding Company Announces Publication in PAIN Journal Regarding Phase 3 Results of the Pivotal Registration Trial of SP-102 (SEMDEXA™) in Lumbosacral Radicular Pain (Sciatica)
|
|
Jun 14
|
Scilex Holding Company (NASDAQ:SCLX) Analysts Just Cut Their EPS Forecasts Substantially
|
|
Jun 13
|
Scilex Holding Company to Present Poster on ELYXYB® (celecoxib oral solution) at the 66th Annual Scientific Meeting of the American Headache Society (AHS) to be Held in San Diego, CA on June 13-16, 2024
|
|
May 30
|
Scilex Holding Company Sends Letters to the U.S. Securities and Exchange Commission and Financial Industry Regulatory Authority Regarding Illegal Market Manipulation of the Common Stock of Scilex Holding Company
|
|
May 14
|
Update: Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute
|
|
May 14
|
Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute
|
|
May 14
|
Scilex Holding Company Announces Final Court Approval of a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex’s intent to Expand the Label for its FDA-Approved Liquid Colchicine P...
|
|
May 14
|
SCLX Grows Revenue and Expands Portfolio
|
|
May 13
|
Scilex Holding Company Provides Information to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock
|
|
Apr 25
|
Scilex Holding Company Announces Closing of $15 Million Registered Direct Offering
|
|
Apr 24
|
Scilex Holding Company Announces $15 Million Registered Direct Offering
|
|
Apr 16
|
Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross and Net Sales for ZTlido® for the First Quarter 2024; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other...
|
|
Apr 9
|
Scilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido® and ELYXYB® for Commercially Insured Patients and the addition of ELYXYB® to a Multi-State Medicaid Pharmaceutical Purchasing Group to Its Purchasing Pool
|
|
Mar 27
|
Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend
|
|
Mar 21
|
Scilex Holding Company Announces New Out-of-Pocket Costs for Commercially Insured Patients
|